# Perceptive Advisors

> Perceptive Advisors is a VC fund backing Biotechnology and Health Care. See 320 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 320
- Last investment: Aug 2026
- Lead investor: 33%
- Fund size: $515M
- Last fund: May 2021
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/perceptive-advisors-llc/about/
- Website: http://www.perceptivelife.com/

Perceptive Advisors is a privately owned hedge fund sponsor. The firm invests in the public equity markets across the globe. It employs a long/short equity strategy as a hedging technique while investing. The firm typically invests in the biotechnology and life sciences sectors to make its investments. Perceptive Advisors is based in New York,New York.

## Contacts

5 contacts available for Perceptive Advisors. Shizune tracks 9 team members at Perceptive Advisors. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/perceptive-advisors?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 178 | 56% |
| Health Care | 135 | 42% |
| Medical | 88 | 28% |
| Therapeutics | 73 | 23% |
| Pharmaceutical | 70 | 22% |

54 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Equity | 78 | 24% |
| Series B | 55 | 17% |
| Series C | 43 | 13% |
| Series A | 26 | 8% |
| Post-IPO Debt | 18 | 6% |

16 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 180 | 56% |
| United Kingdom | 9 | 3% |
| Canada | 6 | 2% |
| France | 6 | 2% |
| China | 4 | 1% |

14 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Ellen Hukkelhoven | Head of Investment Research | 9 | https://shizune.co/investors/profile/ellen-hukkelhoven |
| Fred Callori | Managing Director of Venture | 8 | https://shizune.co/investors/profile/fred-callori |
| Joseph Edelman | CEO & Founder | 11 | https://shizune.co/investors/profile/joseph-edelman |
| Orly Mishan | Managing Director, Perceptive Discovery | 0 | https://shizune.co/investors/profile/orly-mishan |
| Adam Stone | Chief Investment Officer | 8 | https://shizune.co/investors/profile/adam-stone-5 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Ensysce Biosciences | Ensysce Biosciences develops oral drug delivery technologies targeting opioid misuse and overdose. Its Trypsin-Activated Abuse Protection (TAAP™) platform activates medications only upon ingestion, minimizing abuse through non-oral routes. The Multi-Pill Abuse Resistance (MPAR®) system adds a safeguard against overdose by inhibiting drug activationwhen excessive doses are consumed. These platforms are applied to treatments for severe pain and opioid use disorder, including PF614 and PF9001. Ensysce's approach has received recognition from the FDA, with TAAP™ designated as a Fast Track development and MPAR® as a Breakthrough Therapy. The company is also exploring the use of nafamostat, a component of its overdose protection products, for treating infections and pulmonary diseases. Its pipeline includes clinical and preclinical programs focused on enhancing the safety of prescription medications. Ensysce’s products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. | $21.5M | Post-IPO Equity | Aug 06, 2026 |  |
| Entera Bio | Entera Bio is developing novel oral drugs by utilizing its proprietary cutting edge delivery technology This technology protects large molecules and peptides in the GI tract. Oral drug delivery is the most straight forward and user friendly approach to medical treatment. Entera Bio has key personnel with the relevant know how, experience andnetworks working together to enable rapid development of its products. The company has an experienced management team with more than 50 years of combined drug development experience. | $275M | Post-IPO Equity | Jul 27, 2026 |  |
| Freenome | Freenome is a biotechnology company developing blood tests for early cancer detection to improve access to routine screening. | $240M | Post-IPO Equity | Jul 20, 2026 |  |
| CereVasc | CereVasc is a medical device company that develops treatments for neurological diseases, with a primary focus on communicating hydrocephalus. The company is advancing the eShunt® System, an investigational device designed to manage cerebrospinal fluid through a minimally invasive endovascular approach rather than traditional open neurosurgery. Itstechnology includes an implantable cerebrospinal fluid shunt and associated delivery components intended to treat hydrocephalus while reducing the need for invasive surgical procedures. CereVasc conducts clinical studies to evaluate the safety and effectiveness of the eShunt System in patients with conditions such as normal pressure hydrocephalus and other forms of communicating hydrocephalus. The company’s work centers on developing device-based therapies that improve access to treatment for patients with neurological disorders. | $85M | Series C | Jun 04, 2026 |  |
| Quince Therapeutics | Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currentlytesting several potential lead therapeutics in preclinical studies. | $115M | Post-IPO Equity | May 18, 2026 |  |
| Valneva | Valneva is a pharmaceutical company developing prophylactic vaccines to treat infectious diseases. The company focused on developing and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs. Valneva has leveraged its expertise and capabilities both to commercialize two vaccines successfully and torapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus, and COVID-19. | $43.1M | Post-IPO Equity | Apr 30, 2026 |  |
| Adlai Nortye | Adlai Nortye is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with its R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, it has built a global pipeline through collaborations and internal discoveries with more than 10 drug candidates indevelopment. | $150M | Post-IPO Equity | Apr 16, 2026 |  |
| Kiora Pharmaceuticals | EyeGate Pharmaceuticals is a clinical-stage specialty pharmaceutical company that develops medicines to treat eye diseases using its non-invasive, iontophoretic drug-delivery system. It is developing a proprietary platform of medicines to treat diseases of the eye using its unique, non-invasive, iontophoretic drug-delivery system called EyeGateÂII. This proprietary technology platform is based on over 10-years of development at the Bascom Palmer Eye Institute at the University of Miami and has been tested extensively in both pre-clinical and human studies in Europe. Because of the human eye's special anatomy, effective delivery of medicines to treat chronic diseases in the mid and posterior segments of the eye is less than adequate. They believe the EyeGate II Delivery System will offer both physicians and patients an important new alternative in advancing the treatment of eye disease. | $5M | Post-IPO Equity | Apr 07, 2026 |  |
| Diamyd Medical | Diamyd Medical develops the diabetes vaccine Diamyd®, an antigen-specific immunotherapy based on the exclusively licensed GAD-molecule. GABA constitutes alongside with the diabetes vaccine a key asset in Diamyd Medical and the Company uses its GABA in-licensed technology to develop a proprietary GABA drug product.Diamyd Medical’s shares aretraded on Nasdaq Stockholm First North, ticker DMYD B. | $24.9M | Post-IPO Equity | Mar 23, 2026 |  |
| Imperative Care | Imperative Care focuses on developing a portfolio of innovative solutions to address the vast and urgent unmet needs in stroke care. It focuses on medical technology designed to expedite and improve the effectiveness of treatment, giving patients a chance for optimal recovery. | $100M | Convertible Note | Mar 17, 2026 |  |

10 of 320 investments shown.

## Co-investors
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 65 deals together
- [Surveyor Capital](https://shizune.co/investors/profile/surveyor-capital) — VC Fund, 34 deals together
- [RTW Investments](https://shizune.co/investors/profile/rtw-investments-llc) — VC Fund, 32 deals together
- [Janus Henderson Investors](https://shizune.co/investors/profile/janus-henderson-investors) — VC Fund, 31 deals together
- [Cormorant Asset Management](https://shizune.co/investors/profile/cormorant-asset-management) — VC Fund, 29 deals together
- [Redmile Group](https://shizune.co/investors/profile/redmile-group) — VC Fund, 29 deals together

## Similar investors

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

## FAQ

### What does Perceptive Advisors invest in?

Perceptive Advisors invests primarily in Biotechnology, Health Care and Medical startups, most often at Post-IPO Equity and Series B stage. Most of the 320 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Perceptive Advisors?

Public channels for Perceptive Advisors include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Perceptive Advisors?

The team at Perceptive Advisors includes Ellen Hukkelhoven (Head of Investment Research), Fred Callori (Managing Director of Venture) and Joseph Edelman (CEO & Founder), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co